Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Hemic and Lymphatic Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Top 5 Target | Count |
---|---|
Bacterial DNA gyrase x Topoisomerase IV | 1 |
CEN(cap-dependent endonuclease) | 1 |
Mechanism Bacterial DNA gyrase inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date27 May 2016 |
Target |
Mechanism CEN inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Oct 2023 |
Sponsor / Collaborator |
Start Date15 Jun 2023 |
Sponsor / Collaborator |
Start Date01 Apr 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nemonoxacin Malate ( Bacterial DNA gyrase x Topoisomerase IV ) | - | Phase 3 |
TG-1000 ( CEN ) | Influenza A virus infection More | Phase 3 |
Volaprevir combo | Hepatitis C More | Phase 3 |
Blissaff | Hematologic Neoplasms More | Phase 2 |
TG-5 ( Protease ) | Severe Acute Respiratory Syndrome More | Discontinued |